Vcare 2024 Annual Review
Published Time:
2025-01-27 18:01
Source:
I. Innovative Drug R&D Has Witnessed Multiple Significant Advances
① Vicagrel Capsules (anti-platelet):
China: Preparing NDA submission
US: IND approved by FDA
② VC005 Tablets (next-gen selective JAK1 inhibitor):
Phase III for moderate-severe atopic dermatitis: 1st patient enrolled
Phase III for ankylosing spondylitis: Initiated
③ VC005 Gel (topical JAK1 inhibitor):
Phase II for mild-moderate atopic dermatitis: Initiated
II. Patent Layout for Innovative Drugs
Filed 10 patent applications; Granted 7 patents.
III. Sustained Revenue Growth
2024 revenue: ~RMB 440 million; Contract value: ~RMB 690 million.
IV. Strategic Corporate Development
① Closed Series C+ financing (~RMB 200M); Completed shareholding reform.
② Commenced photovoltaic power project construction.
③ Completed warehouse expansion & lab renovation.
④ Tianshu Pharmaceutical Phase I facility passed final acceptance.
V. Accelerated Group Digitalization
① Completed Phase II: CRM platform & data middleware established.
② Launching Phase III: R&D & production project management systems.
VI. Employee Care Highlights
① Organized 8 cultural events
② Held 12 Happy Hour activities
③ Completed 115 promotions
④ ~70 employees received equity incentives
⑤ Conducted 400+ internal trainings
⑥ Hosted 10+ external expert lectures
VII. Honors & Qualifications
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
Nanjing Vcare Honored As: Top 20 CRO Enterprises in China; Jiangsu Provincial Three-Star Cloud-Adopted Enterprise; Nanjing Engineering Research Center for Synthetic Biology & Flow Chemistry
Related News
16
2021
/
08
Jiangsu Vcare's Class 1 Innovative Drug VC005 Tablets Receives Clinical Trial Approval
In August 2021, VC005 tablets, an innovative drug developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received clinical trial approval from the NMPA for the indication of inflammatory bowel disease (IBD), with clinical trials set to begin shortly.
View Details
29
2021
/
07
Jiangsu Vcare Secures New Round of Financing Totaling CNY 100 Million
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) secures another strategic investment of CNY 100 million. This round was jointly invested by Nanjing NII Group, Renpu Capital, and Nanjing Innovation Capital Group. The funds will primarily be used to advance the clinical research of innovative drug pipeline projects like Vicagrel and VC004, while accelerating strategic layout in the CDMO business sector.
View Details
24
2021
/
06
Vcare Pharmatech Selected as 2021 Nanjing Nurtured Unicorn Enterprise
On June 23, 2021, the list of Nanjing Unicorn and Gazelle Enterprises was announced. Jiangsu Vcare Pharmatech Technology Co., Ltd.(Vcare Pharmatech) was selected as a 2021 Nanjing Nurtured Unicorn Enterprise.
View Details
22
2021
/
03
Jiangsu Vcare's Novel Drug Vicagrel Receives FDA Approval for Clinical Trials
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced encouraging news regarding its novel antiplatelet drug Vicagrel: The US FDA has provided feedback on the company's submitted IND application for Vicagrel, permitting the company to initiate clinical trials.
View Details
12
2021
/
03
Jiangsu Vcare Completes Pre-IND Submission for VC005, a Highly Selective JAK1 Inhibitor New Drug
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a Pre-IND application to the NMPA for its VC005 tablets. VC005 is a highly selective JAK1 inhibitor independently designed by Jiangsu Vcare. It is intended for the clinical treatment of inflammatory bowel disease (IBD), an intestinal autoimmune disorder.
View Details
08
2021
/
03
Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Financing Round
Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) has secured financing worth hundreds of millions of CNY in a round led by SDIC Capital, with participation from Fengling Capital. The funds will accelerate Vcare’s CDMO expansion and Phase III clinical research for its innovative drug Vicagrel.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn